Yoshinari K, Aoki M, Ohtsuka T, Nakayama N, Itezono Y, Mutoh M, Watanabe J, Yokose K
Nippon Roche Research Center, Kamakura, Japan.
J Antibiot (Tokyo). 1994 Dec;47(12):1376-84. doi: 10.7164/antibiotics.47.1376.
Panclicins A-E are novel and potent pancreatic lipase inhibitors produced by Streptomyces sp. NR 0619. Their structures have been elucidated based on NMR and FAB-MS experiments. The relative configurations have also been determined by NMR experiments. The absolute stereochemistry has been determined by the chiral HPLC analysis of the hydrolysates of panclicins A and B and by modified Mosher's method on a derivative of panclicin A. They are structurally related to beta-lactone esterase inhibitors of microbial origin, lipstatin, valilactone, ebelactones and esterastin. Panclicins also contain a beta-lactone structure with two alkyl chains, one of which has an N-formylalanyloxy or N-formylglycyloxy substituent.
泛青霉素A - E是由链霉菌属NR 0619产生的新型强效胰脂肪酶抑制剂。基于核磁共振(NMR)和快原子轰击质谱(FAB - MS)实验阐明了它们的结构。相对构型也通过NMR实验确定。绝对立体化学通过对泛青霉素A和B水解产物的手性高效液相色谱(HPLC)分析以及对泛青霉素A衍生物采用改良的莫舍尔方法确定。它们在结构上与微生物来源的β - 内酯酯酶抑制剂、脂抑素、缬内酯、埃博内酯和酯抑素相关。泛青霉素还含有一个带有两条烷基链的β - 内酯结构,其中一条具有N - 甲酰丙氨酰氧基或N - 甲酰甘氨酰氧基取代基。